At the intersection of neuroscience and speculative ambition, Ray Kurzweil has lent his name and vision to Subsense, a startup proposing to reach the human brain not through surgery but through the nose — delivering nanoparticles that would read and stimulate neural activity in concert with an external wearable. The company, backed by $27 million and eyeing clinical pilots in the late 2020s, represents a genuine conceptual departure from implant-based competitors, though the distance between its theoretical elegance and proven human safety remains vast. Whether this marks a meaningful step tow